UCB SA (OTCMKTS:UCBJY) Short Interest Update

UCB SA (OTCMKTS:UCBJY - Get Free Report) saw a significant increase in short interest in February. As of February 28th, there was short interest totalling 13,900 shares, an increase of 363.3% from the February 13th total of 3,000 shares. Approximately 0.0% of the shares of the stock are short sold. Based on an average daily trading volume, of 92,400 shares, the short-interest ratio is presently 0.2 days.

UCB Trading Up 0.2 %

Shares of UCBJY stock traded up $0.15 during midday trading on Friday, reaching $98.26. 12,149 shares of the company traded hands, compared to its average volume of 42,235. The firm's 50 day simple moving average is $97.56 and its two-hundred day simple moving average is $95.36. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.19 and a quick ratio of 0.78. UCB has a 1-year low of $56.77 and a 1-year high of $106.60.

About UCB

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.